Clinical Practice and Guidelines for Managing Antithrombotics before and after Endoscopy: A National Survey Study

다국어 초록 (Multilingual Abstract)

Background/Aims: The proper handling of antithrombotics is critical, and this study aimed to assess guideline adherence in the management of antithrombotics before and after endoscopy. Methods: A survey questionnaire was developed. The respondents’ demographic information was included, and the questionnaire was divided into the first section for forceps biopsy, the second for polypectomy, and the third for endoscopic submucosal dissection (ESD) in which aspirin, clopidogrel, combination therapy (aspirin and clopidogrel), warfarin, and direct oral anticoagulants (apixaban) were prescribed to imaginary patients. Results: A total of 415 endoscopists completed this survey (response rate of 6.2%, 415/6,673). The percentage of respondents who chose to proceed with biopsy for patients taking aspirin, those taking clopidogrel, those under combination therapy, those taking warfarin, and those taking apixaban was 89.4%, 74.2%, 61.0%, 38.6%, and 50.4%, respectively. Most respondents answered that they would discontinue aspirin, clopidogrel, and a combination of both drugs for 5 days before polypectomy or ESD (69.4%/76.9%, 83.6%/83.9%, and 53.3%/65.8%, respectively). The answers indicated that warfarin should be discontinued with heparin bridge therapy in high thromboembolic risk patients (polypectomy 70.1%, ESD 73.5%). Regarding apixaban use in polypectomy and ESD, 63.9% and 58.1% of respondents, respectively, chose answers consistent with the guidelines. Conclusions: The gap between the guidelines and clinical practice in the management of antithrombotics before and after endoscopy is considerable and should be addressed via educational strategies.

참고문헌 (Reference)

1 Schoenfeld P, "Why don’t endoscopists follow guideline recommendations and how can we improve adherence?" 50 : 93-95, 2018

2 ASGE Standards of Practice Committee, "The management of antithrombotic agents for patients undergoing GI endoscopy" 83 : 3-16, 2016

3 Gessl I, "Surveillance colonoscopy in Austria: are we following the guidelines?" 50 : 119-127, 2018

4 Igarashi K, "Should antithrombotic therapy be stopped in patients undergoing gastric endoscopic submucosal dissection" 31 : 1746-1753, 2017

5 Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation" 365 : 883-891, 2011

6 Hui AJ, "Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents : analysis of 1657 cases" 59 : 44-48, 2004

7 Feuerstein JD, "Multicenter study assessing physician recommendations regarding the continuation of aspirin and/or NSAIDs prior to gastrointestinal endoscopy" 60 : 3234-3241, 2015

8 Greenwald DA, "Managing antithrombotic agents during endoscopy" 30 : 679-687, 2016

9 Lee SY, "Managing anticoagulation and antiplatelet medications in GI endoscopy : a survey comparing the East and the West" 67 : 1076-1081, 2008

10 Chan FKL, "Management of patients on antithrombotic agents undergoing emergency and elective endoscopy : joint Asian Pacific Association of Gastroenterology(APAGE)and Asian Pacific Society for Digestive Endoscopy(APSDE)practice guidelines" 67 : 405-417, 2018

11 Whitson MJ, "Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel? A prospective, randomized study involving 630 biopsies" 45 : 228-233, 2011

12 Abraham NS, "Gastrointestinal bleeding in cardiac patients : epidemiology and evolving clinical paradigms" 30 : 609-614, 2014

13 Veitch AM, "Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants : British Society of Gastroenterology(BSG)and European Society of Gastrointestinal Endoscopy(ESGE)guidelines" 65 : 374-389, 2016

14 Dong J, "Effects of antithrombotic therapy on bleeding after endoscopic submucosal dissection" 86 : 807-816, 2017

15 Feuerstein JD, "Current knowledge of antibiotic prophylaxis guidelines regarding GI open-access endoscopic procedures is inadequate" 82 : 268-275, 2015

16 Ono S, "Controversy on the management of anticoagulants and antiplatelet agents for scheduled endoscopy" 23 : 1-4, 2011

17 Ono S, "Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan" 26 : 1434-1440, 2011

18 Woolf SH, "Clinical guidelines : potential benefits, limitations, and harms of clinical guidelines" 318 : 527-530, 1999

19 Manocha D, "Bleeding risk after invasive procedures in aspirin/NSAID users : polypectomy study in veterans" 125 : 1222-1227, 2012

20 Cho SJ, "Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms" 44 : 114-121, 2012

21 Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation" 365 : 981-992, 2011

22 Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS" 18 : 1609-1678, 2016

23 January CT, "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society" 130 : 2071-2104, 2014

24 Camm AJ, "2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association" 33 : 2719-2747, 2012